SIMPONI ARIA SKIN

For members who have previously received a biologic or targeted synthetic DMARD (e.g.

Moderately to severely active rheumatoid arthritis (RA).

SIMPONI ARIA SKIN

Intravenous golimumab (Simponi Aria)Īetna considers intravenously administered golimumab (Simponi Aria) medically necessary for the following indications, where the member has had a documented negative TB test (which can include a tuberculosis skin test (PPD), an interferon-release assay (IGRA), or a chest x-ray) Footnote1* within 6 months of initiating therapy for persons who are naive to biologic DMARDs or targeted synthetic DMARDs associated with an increased risk of TB: For information on site of service for Simponi Aria infusions, see Utilization Management Policy on Site of Care for Specialty Drug Infusions. Note: Site of Care Utilization Management Policy applies to Simponi Aria. Medicare Part B plans: Precertification of intravenous golimumab (Simponi Aria) is required of participating providers and members in applicable Medicare Part B plan designs. Note: Simponi Aria (golimumab intravenous) requires precertification:Ĭommercial plans: Precertification of intravenous golimumab (Simponi Aria) is required of all Aetna participating providers and members in applicable plan designs.

Simponi aria